StockNews.AI
VEEV
StockNews.AI
161 days

Boehringer Ingelheim Partners with Veeva to Launch 'One Medicine Platform'

1. Veeva partners with Boehringer for One Medicine Platform implementation. 2. The platform streamlines clinical, regulatory, and quality data processes. 3. It aims to accelerate drug development for incurable diseases. 4. Veeva's Development Cloud enhances trial efficiency and collaboration. 5. Commitment to innovative and life-transforming treatments for patients is emphasized.

7m saved
Insight
Article

FAQ

Why Bullish?

This collaboration enhances Veeva’s market position and growth prospects, similar to past partnerships that led to significant revenue increases.

How important is it?

The implementation of the Veeva Development Cloud with a major biopharma enhances Veeva's credibility and expected revenue growth.

Why Long Term?

Strategic partnerships like this often require time to manifest in sales and stock performance, reflecting long-term potential.

Related Companies

Boehringer Ingelheim
Top 20 biopharma goes live with Veeva Development Cloud to speed the delivery of treatments for currently incurable diseases , /PRNewswire/ -- Today, Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) have announced the launch of Boehringer's One Medicine Platform, powered by the successful implementation of Veeva Development Cloud. They first announced the One Medicine collaboration in March 2022. The unified platform brings together data and processes across clinical, regulatory, and quality, enabling Boehringer to streamline its product development. With the One Medicine Platform, Boehringer can seamlessly connect data across functions, optimize trial efficiency and collaboration with research sites, and accelerate the delivery of new medicines to treat currently incurable diseases. "Together with Veeva, Boehringer has advanced its approach to clinical trials and is fulfilling our pledge to accelerate the delivery of innovative, life-transforming treatments to patients across the world," said Oliver Fink, head of learning, process and digitalization at Boehringer Ingelheim. "Veeva Development Cloud provides the technology foundation for Boehringer's One Medicine Platform, giving our teams the flexibility to design and run studies with greater speed, efficiency, and compliance." "By connecting clinical, regulatory, and quality on Veeva Development Cloud, Boehringer unifies data and breaks down silos across teams to accelerate drug development and approvals," said Rik van Mol, senior vice president, Veeva Development Cloud. "This is an exciting milestone toward realizing Veeva and Boehringer's shared mission to advance the use of data and technology to modernize clinical trials and deliver better patient outcomes." Veeva Development Cloud is the technology foundation for product development, bringing together clinical, quality, regulatory, and safety applications to simplify end-to-end business processes and deliver process excellence. Additional InformationFor more on Veeva Development Cloud, visit: veeva.com/DevelopmentCloud About Boehringer IngelheimBoehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Learn more at https://www.boehringer-ingelheim.com. About Veeva SystemsVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com. Veeva Forward-looking StatementsThis release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10- Q for the period ended October 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 36 and 37), and in our subsequent SEC filings, which you can access at sec.gov. SOURCE Veeva Systems WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News